2.2 1.23 mg/m2 is administered intravenously over 2 to 5 minutes on days 1 and 8 of every 21‑day cycle.
2.3 £361.00 per 0.88 mg/2 ml solution for injection vial and £541.50 per 1.32 mg/3 ml solution for injection vial (excluding VAT; British national formulary [BNF] online, accessed October 2017). The company has agreed a patient access scheme with the Department of Health. If eribulin had been recommended, this scheme would provide a simple discount to the list price of eribulin with the discount applied at the point of purchase or invoice. The level of the discount is commercial in confidence. The Department of Health considered that this patient access scheme would not constitute an excessive administrative burden on the NHS.